The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Treatment following progression on first-line IO in dMMR/MSI-H mCRC
Sara Lonardi, MD, Veneto Institute of Oncology, Padua, Italy, discusses the approach to deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) patients who progress on first-line immunotherapy (IO) doublet therapy, highlighting that while a significant proportion of patients experience long progression-free survival, those who do progress have various salvage options, including standard chemotherapy, encorafenib and cetuximab for BRAF-mutated tumors, and potentially other immunotherapeutic strategies. Dr Lonardi notes that the choice of subsequent treatment depends on several factors, including the presence of specific mutations such as BRAF. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
